1461003
USP
Niacin
United States Pharmacopeia (USP) Reference Standard
동의어(들):
Nicotinic acid, 3-Picolinic acid, Niacin, Pellagra preventive factor, Pyridine-3-carboxylic acid, Vitamin B3
로그인조직 및 계약 가격 보기
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C6H5NO2
CAS 번호:
Molecular Weight:
123.11
Beilstein:
109591
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
Grade
pharmaceutical primary standard
API family
nicotinic acid
제조업체/상표
USP
기술
HPLC: suitable
mp
236-239 °C (lit.)
solubility
ethanol: 12.5 g/L at 25 °C
water: soluble 180 g/L at 20 °C
density
1.473 g/cm3 at 25 °C
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
OC(=O)c1cccnc1
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChI key
PVNIIMVLHYAWGP-UHFFFAOYSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Niacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Niacin Tablets
- Niacin Injection
- Niacin Extended-Release Tablets
- Inositol Niacinate
- Niacinamide
- Water-Soluble Vitamins Capsules
분석 메모
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
기타 정보
Sales restrictions may apply.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Eye Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point (°F)
379.4 °F - closed cup
Flash Point (°C)
193 °C - closed cup
Vaijinath S Kamanna et al.
Current opinion in lipidology, 24(3), 239-245 (2013-04-27)
This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis. Emerging findings indicate that niacin decreases hepatic triglyceride synthesis and subsequent VLDL/LDL secretion by directly and noncompetitively inhibiting hepatocyte diacylglycerol
James B Kirkland
Mutation research, 733(1-2), 14-20 (2011-12-06)
Through its involvement in over 400 NAD(P)-dependent reactions, niacin status has the potential to influence every area of metabolism. Niacin deficiency has been linked to genomic instability largely through impaired function of the poly ADP-ribose polymerase (PARP) family of enzymes.
Matilda Florentin et al.
Current vascular pharmacology, 9(4), 385-400 (2011-02-15)
Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional
Janet E Digby et al.
Current opinion in lipidology, 20(4), 321-326 (2009-06-06)
Nicotinic acid is the most potent treatment clinically available for lowering LDL cholesterol and VLDL cholesterol and raising HDL cholesterol. The strong inverse relationship between coronary heart disease risk and HDL cholesterol at all levels of LDL cholesterol has, therefore
E T Bodor et al.
British journal of pharmacology, 153 Suppl 1, S68-S75 (2007-11-27)
Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.